BioSpace News Archive

Indee Labs announces an exclusive marketing and distribution deal with Sunko Instruments in China for Hydropore Research Use Only.

Hepagene Therapeutics, Inc. today announced that Hepagene will present two posters highlighting the preclinical and clinical development for its two non-alcoholic steatohepatitis (NASH) programs at the European Association for the Study of the Liver (EASL) Congress, taking place in Vienna Austria, June 21-24, 2023.

StemCyte announced it has officially begun recruiting patients under a US Food and Drug Administration (FDA) approved Phase IIa human clinical trial in the United States.

Today, the U.S. Food and Drug Administration approved the oral antiviral Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that on May 24, 2023 it received 510(k) clearance of its coactiv+™ Antimicrobial Wound Gel from the U.S. Food and Drug Administration (FDA) for the management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns.

Brain Cancer Canada, a leading charity in the fight against brain cancer, is delighted to announce a $50,000 research grant to Dr. Amit Singnurkar at Sunnybrook Health Sciences Centre.

On May 19, 2023, Krystal Biotech, a client of Berkshire Sterile Manufacturing (BSM), received FDA approval for VYJUVEK™, the first-ever topical gene therapy approved to treat dystrophic epidermolysis bullosa (DEB) in children and adults six months of age or older.

AlloSource®, one of the largest nonprofit allograft providers in the U.S. creating innovative cellular and tissue products to help surgeons heal their patients, today announced the launch of AlloMend® Duo Acellular Dermal Matrix (ADM), a natural solution for soft tissue reconstruction.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) approved PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that all proposed resolutions submitted to the Annual General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST.